All In Biotech

Drug Trial Radar · NCT05816642

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

A Prospective Observational Study of Molecular Classification and Circulating Tumor DNA Dynamic Monitoring to Explore Related Factors That Predict the Efficacy of Single Targeted Therapy or Combined With Immunotherapy for Metastatic Renal Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Aug 1, 2022

Primary completion

Dec 31, 2023

Study completion Dec 31, 2024

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; West China Hospital; Xiangya Hospital of Central South University; Fudan University; Second Affiliated Hospital, Zhejiang University, School of Medicine; Second Affiliated Hospital of Nantong University; Peking University First Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Zhejiang University; First Affiliated Hospital of Wenzhou Medical University; Sir Run Run Shaw Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The General Hospital of Eastern Theater Command; The First Affiliated Hospital with Nanjing Medical University; The First Affiliated Hospital of University of Science and Technology of China; The Second Hospital of Anhui Medical University; Tongji Hospital; The First Affiliated Hospital of Zhengzhou University; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital; The First Affiliated Hospital of Shanxi Medical University; Shanxi Province Cancer Hospital; Changzhi Medical College; First Affiliated Hospital Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Air Force Medical University; Tang-Du Hospital; Quanzhou First Hospital; Third Affiliated Hospital, Sun Yat-Sen University
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

  • sunitinib or pazopanibDrug

    Single targeted therapy

  • PD-1 inhibitor combined with axitinibDrug

    targeted therapy combined with immunotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survivalTime frame: From drug taken until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital, School of Medicine, Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.